Article
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.
Molecular cancer therapeutics - 1 Oct 2017
Ang Joo Ern, Pal Akos, Asad Yasmin J, Henley Alan T, Valenti Melanie, Box Gary, de Haven Brandon Alexis, Revell Victoria L, Skene Debra J, Venturi Miro, Rueger Ruediger, Meresse Valerie, Eccles Suzanne A, de Bono Johann S, Kaye Stanley B, Workman Paul, Banerji Udai, Raynaud Florence I
Abstract excerpt
MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we identified in preclinical models 21 plasma metabolites including amino acids, propionylcarnitine, phosphatidylcholines, and sphingomyelins that were significantly altered in two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.